Home Cart Sign in  
Chemical Structure| 445303-12-8 Chemical Structure| 445303-12-8

Structure of 445303-12-8

Chemical Structure| 445303-12-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 445303-12-8 ]

CAS No. :445303-12-8
Formula : C14H19BO3
M.W : 246.11
SMILES Code : CC1(C)C(C)(C)OB(C2=CC=C3CCOC3=C2)O1
MDL No. :MFCD10699453
InChI Key :WLLNCSSMFWOCNN-UHFFFAOYSA-N
Pubchem ID :16750379

Safety of [ 445303-12-8 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 445303-12-8 ] Show Less

Physicochemical Properties

Num. heavy atoms 18
Num. arom. heavy atoms 6
Fraction Csp3 0.57
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 0.0
Molar Refractivity 72.26
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

27.69 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.0
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.91
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.92
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.67
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.38
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.78

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.38
Solubility 0.103 mg/ml ; 0.000417 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.15
Solubility 0.173 mg/ml ; 0.000704 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.29
Solubility 0.0125 mg/ml ; 0.0000508 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

Yes
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

Yes
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

Yes
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.74 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.98

Application In Synthesis of [ 445303-12-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 445303-12-8 ]

[ 445303-12-8 ] Synthesis Path-Downstream   1~2

YieldReaction ConditionsOperation in experiment
With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)*CH2Cl2; potassium acetate; In 1,4-dioxane; cyclohexane; at 85℃;Inert atmosphere; General procedure: A solution of compound (125c) (1.92 g, 6.82 mmol), bis(pinacolato)diboron (2.6 g, 10.24 mmol) and potassium acetate (2.01 g, 20.49 mmol) in dry 1,4-dioxane (45 mL) was degassed under argon for 10 minutes. The Catalyst Pd(dppf)Cl2·CH2Cl2 (279 mg, 0.34 mmol) was added and the reaction mixture was stirred at 85C overnight. The reaction mixture was filtered through celite and concentrated under reduced pressure. The residue was diluted with ethyl acetate and washed with a saturated aqueous solution of sodium hydrogencarbonate. The combined organic phases were dried over sodium sulfate, filtered and concentrated. The crude product was triturated in cyclohexane and filtered to afford compound (125d) as a brown solid (1.76 g, 78%) which was engaged in the following step without additional purification. 1H NMR (400 MHz, CDCl3) delta 1.37 (s, 12H), 1.73-1.89 (m, 2H), 2.11-2.20 (m, 1H), 2.22-2.30 (m, 1H), 3.68-3.74 (m, 1H), 3.80-3.85 (m, 1H), 3.89-3.94 (m, 1H), 4.12-4.16 (m, 1H), 4.41-4.47 (m, 1H), 7.41 (d, J = 8.2 Hz, 1H), 7.75 (dd, J = 0.9/8.2 Hz, 1H), 8.19 (s, 1H), 8.29 (bt, 1H). MS m/z ([M+H]+) 329.
  • 2
  • [ 445303-12-8 ]
  • tert-butyl [(3S,5R)-1-(3-[(7-bromoquinolin-2-yl)methyl]amino}pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate [ No CAS ]
  • 4-[(3S,5R)-3-amino-5-methylpiperidin-1-yl]-N-[7-(2,3-dihydro-1-benzofuran-6-yl)quinolin-2-yl]methyl}pyridin-3-amine [ No CAS ]
YieldReaction ConditionsOperation in experiment
6-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydro-l-benzofuran (from Ark Pharma, 0.018 g, 0.072 mmol), fert-butyl [(35',5i?)-l-(3-[(7-bromoquinolin-2- yl)methyl]amino}pyridin-4-yl)-5-methylpiperidin-3-yl]carbamate (16.0 mg, 0.03 mmol), 1,4- dioxane (0.17 mL) and DIPEA (17.3 mg, 0.134 mmol) and water (0.017 mL) were mixed together. The mixture was flushed with nitrogen and then bis(tri-fer/- butylphosphine)palladium (7.0 mg, 0.01 mmol) was added. The reaction mixture was sealed and heated at 120 C for 2 h. The reaction mixture was cooled, filtered and concentrated under vacuum. The residue was dissolved in MeOH (1 mL), followed by the addition of 4 N HC1 in dioxane (2.0 mL) to the resultant solution. The reaction mixture was stirred at room temperature for 2 h, and the solvents were removed under vacuum. The residue was purified by prep LCMS (XBridge PrepC18 5muiotaeta OBD column, 30x10 mm, 60 mL/min, gradient elution with MeCN and water with NH4OH) to give the desired product as a white powder. LCMS calc. for C29H32N5O (M+H)+: m/z = 466.3. Found: 466.3.
 

Historical Records

Categories

Related Functional Groups of
[ 445303-12-8 ]

Organoborons

Chemical Structure| 937591-69-0

A237346 [937591-69-0]

2-(2,3-Dihydrobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.99

Chemical Structure| 754226-40-9

A323812 [754226-40-9]

2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.95

Chemical Structure| 765908-38-1

A276366 [765908-38-1]

2-(3-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.94

Chemical Structure| 1009303-77-8

A357377 [1009303-77-8]

2-Methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenemethanol

Similarity: 0.91

Chemical Structure| 1002727-88-9

A165636 [1002727-88-9]

2-(Chroman-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.90

Related Parent Nucleus of
[ 445303-12-8 ]

Benzofurans

Chemical Structure| 937591-69-0

A237346 [937591-69-0]

2-(2,3-Dihydrobenzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.99

Chemical Structure| 519054-55-8

A327970 [519054-55-8]

2-(Benzofuran-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.90

Chemical Structure| 1192755-14-8

A145167 [1192755-14-8]

2-(Benzofuran-7-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.86

Chemical Structure| 763120-44-1

A221632 [763120-44-1]

(2,3-Dihydrobenzofuran-6-yl)boronic acid

Similarity: 0.78

Chemical Structure| 227305-69-3

A137520 [227305-69-3]

2,3-Dihydrobenzofuran-5-boronic acid

Similarity: 0.76